Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member

Search

1737793

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of running a public awareness campaign to remove all COVID signs.
tabling member constituency	Great Yarmouth
tabling member printed	Rupert Lowe
uin	11724
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>No assessment of the merits of running a public awareness campaign to remove all COVID-19 signs has been made.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 31/10/2024 14:49:55 answering member 1506 label Biography information for Andrew Gwynne
tabling member	5158

1737301

registered interest
date	28/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 October 2024 to Question 6194 on Coronavirus: Vaccination, whether the Medicines and Healthcare products Regulatory Agency has made an assessment of the potential implications for future medical decisions of the Pfizer study abstract entitled, Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine, dated 12 March 2024; and when he plans to publish the full study.
tabling member constituency	Tatton
tabling member printed	Esther McVey
uin	11248
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>The study abstract has been reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA), as part of its continuous post approval safety monitoring procedures for the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty). The abstract is available at the following link:</p><p><a href="https://catalogues.ema.europa.eu/system/files/2024-06/C4591021%20Interim%205%20Study%20Report%20Abstract%20_0.pdf" target="_blank">https://catalogues.ema.europa.eu/system/files/2024-06/C4591021%20Interim%205%20Study%20Report%20Abstract%20_0.pdf</a></p><p>The MHRA does not consider that any regulatory action is warranted at this time and will review the final study report, when it’s made available by Pfizer, as part of safety monitoring procedures.</p><p>The MHRA does not publish study reports for company studies, and further publications of results are the responsibility of Pfizer-BioNTech. The MHRA continues to closely monitor the safety of all COVID-19 vaccines and will take any regulatory action necessary should any new safety concerns be identified.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 31/10/2024 12:59:08 answering member 1506 label Biography information for Andrew Gwynne
tabling member	4084 label Biography information for Esther McVey

1737147

registered interest
date	25/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the number of radiotherapy treatment machines in England.
tabling member constituency	South Holland and The Deepings
tabling member printed	Sir John Hayes
uin	11155
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>The Government knows that cancer patients are waiting too long for a diagnosis and treatment. We will get the National Health Service diagnosing cancer on time, diagnosing it earlier, and treating it faster, so that more patients survive this horrible set of diseases, and we will improve patients’ experience across the system. As part of this, we are committed to bringing down waits for cancer appointments with a Fit for the Future fund, providing investment for the number of computed tomography, magnetic resonance imaging, and other tests that are needed to reduce elective and cancer waiting times, thereby saving lives.</p><p>The Government will continue to support the provision of radiotherapy machines, however, since April 2022 the responsibility for investing in new radiotherapy machines has been with local systems.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 31/10/2024 16:08:52 answering member 4444 label Biography information for Karin Smyth
tabling member	350 label Biography information for Sir John Hayes

1737148

registered interest
date	25/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Radiotherapy: Rural Areas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with NHS England on improving access to radiotherapy treatments for cancer patients in rural areas.
tabling member constituency	South Holland and The Deepings
tabling member printed	Sir John Hayes
uin	11156
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>NHS England and the integrated care boards are responsible for ensuring that the healthcare needs of local communities are met. These responsibilities include considering adequate healthcare provision, care, and wider support for local populations, including in remote and rural areas.</p><p>For those who may struggle to access treatment, the NHS Healthcare Travel Costs Scheme provides financial assistance to patients in England who do not have a medical need for transport, but who require assistance with the costs of travelling to receive certain National Health Services. The NHS Non-Emergency Patient Transport Services provide funded transport where a medical condition means that a patient would struggle to safely attend their treatment independently.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 31/10/2024 15:47:53 answering member 4444 label Biography information for Karin Smyth
tabling member	350 label Biography information for Sir John Hayes

1736889

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Plastics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce the number of single-use items used by the National Health Service.
tabling member constituency	Cannock Chase
tabling member printed	Josh Newbury
uin	11075
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This report is available at the following link:</p><p><a href="https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf" target="_blank">https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2022/07/B1728-delivering-a-net-zero-nhs-july-2022.pdf</a></p><p>In October 2024, the Government published the Design for Life roadmap, a new strategy to transition away from all avoidable single-use medical technology products towards a functioning circular system by 2045. This roadmap is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/design-for-life-roadmap" target="_blank">https://www.gov.uk/government/publications/design-for-life-roadmap</a></p><p>The programme is expected to support the NHS by improving resilience, reducing waste, delivering cost savings, and achieving the NHS commitment to be net zero by 2045. The Design for Life roadmap provides examples of where NHS organisations are already achieving cost, waste, and carbon savings through reusing, remanufacturing, and recycling medical devices and equipment, in line with their local Green Plans.</p><p>In addition, NHS England collaborates with NHS Supply Chain to increase the availability of reusable products, and supports local NHS organisations to use more reusable medical devices and products, where it is safe to do so. For example, NHS England supported the Royal Surgical Colleges to develop the evidence-based Green Theatre Checklist to encourage sustainable theatre approaches, including promoting the use of reusable or remanufactured equipment, where appropriate. Further information on the checklist is available at the following link:</p><p><a href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcsed.ac.uk%2Fprofessional-support-development-resources%2Fenvironmental-sustainability-and-surgery%2Fgreen-theatre-checklist&amp;data=05%7C02%7Cpeter.cockett%40dhsc.gov.uk%7Cf01efded06ed487f31c008dcf771769f%7C61278c3091a84c318c1fef4de8973a1c%7C1%7C0%7C638657317044844782%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=0hYqHXF9AWLMPThOJQOk8sKp18XtE85BVjBeaVrc2qE%3D&amp;reserved=0" target="_blank">https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rcsed.ac.uk%2Fprofessional-support-development-resources%2Fenvironmental-sustainability-and-surgery%2Fgreen-theatre-</a></p><p>Additionally, NHS England is supporting innovation through the Small Business Research Initiative Healthcare programme, which has funded a project to support reuse of surgical textiles, with further information available at the following link:</p><p><a href="https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero" target="_blank">https://sbrihealthcare.co.uk/impact-case-studies/case-studies/revolution-zero</a></p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 17:13:37 answering member 4444 label Biography information for Karin Smyth
tabling member	5034

1736894

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Myasthenia Gravis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of making (a) rozanolixizumab, (b) zilucoplan and (c) efgartigimod available to NHS patients with myasthenia gravis (MG); and what (i) representations his Department has received from and (ii) meetings his Department has had with MG patients on that matter.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr Richard Holden
uin	11055
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>The Department has made no such assessment. The National Institute for Health and Care Excellence (NICE) makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating rozanolixizumab, zilucoplan, and efgartigimod within their licensed indications for the treatment of myasthenia gravis, and has not yet published final guidance.</p><p>The Department has received correspondence letters from constituents via their Member of Parliament regarding myasthenia gravis and the treatment for this condition, but there have not been any recent meetings between Ministers and patients with this condition.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 29/10/2024 16:51:04 answering member 4444 label Biography information for Karin Smyth
tabling member	4813 label Biography information for Mr Richard Holden

1736913

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome and Long Covid
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made with the Chancellor of the Exchequer of the potential impact of (a) ME and (b) long covid on economic growth.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10994
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10995 10996 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13733 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736914

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome and Long Covid
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the delivery plan for ME/CFS will include measures to improve the safety of NHS care for patients with ME.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10995
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10994 10996 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13735 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736915

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Fatigue Syndrome: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of ring-fencing biomedical research funding for ME.
tabling member constituency	Wells and Mendip Hills
tabling member printed	Tessa Munt
uin	10996
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>No assessment has been made on the impact of myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID on economic growth. However, the Government recognises that long-term sickness continues to be the most common reason for economic inactivity among the working age population. As part of the Get Britain Working plan, more disabled people and those with health conditions will be supported to enter and stay in work, by devolving more power to local areas so they can shape a joined-up work, health, and skills offer that suits the needs of the people they serve.</p><p>The Government has established a Growth Mission Board focused squarely on reviving economic growth, and has established a new Growth Delivery Unit in HM Treasury to track and support delivery of key growth priorities.</p><p>The final ME/CFS delivery plan is a priority for the Department, and it is our intention to publish a response summary later this autumn. We cannot comment on the exact content of the final delivery plan at this time, but it will be shaped by the consultation responses, along with continued close engagement with stakeholders, with three broad themes of attitudes and education, research, and living with ME/CFS. We aim to publish this in the winter of 2024/25.</p><p>The Department funds ME/CFS research through the National Institute for Health and Care Research (NIHR). The NIHR and the Medical Research Council (MRC) are committed to funding high-quality research to understand the causes, consequences, and treatment of ME/CFS, and are actively exploring next steps for research in this area. The NIHR welcomes funding applications for research into any aspect of human health, including ME/CFS.</p><p>Ring-fencing funding for ME/CFS has been considered and discussed with the community during the development of the Interim Delivery Plan for ME/CFS, as well as the recent roundtables on ME/CFS and Long COVID. Ring-fencing is not usual practice for research funders as applications in all areas compete for the funding available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all areas, the amount of NIHR funding depends on the volume and quality of scientific activity. Funding for high quality research is available through NIHR programmes, and there is support available for researchers to successfully apply for these awards.</p><p>Over the last five years, the NIHR has invested over £3.6 million in research programme funding for ME/CFS. This includes over £1.5 million to the DecodeME study, co-funded with the MRC, which aims to understand if there is a genetic component to the condition, and in doing so increase our understanding of ME/CFS to support the development of diagnostic tests and targeted treatments.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne grouped question UIN 10994 10995 question first answered 30/10/2024 16:30:29 answering member 1506 label Biography information for Andrew Gwynne previous answer version 13734 answering member constituency Gorton and Denton answering member printed Andrew Gwynne answering member 1506 label Biography information for Andrew Gwynne
tabling member	4089 label Biography information for Tessa Munt

1736935

registered interest
date	24/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Act 1983
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when his Department plans to bring forward legislative proposals to update the Mental Health Act 1983.
tabling member constituency	Sheffield Central
tabling member printed	Abtisam Mohamed
uin	11096
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>The Mental Health Bill announced in the King’s Speech will deliver the Government’s commitment to modernise the Mental Health Act 1983. The bill will be published when Parliamentary time allows.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 31/10/2024 11:39:36 answering member 4359 label Biography information for Stephen Kinnock
tabling member	5142